SPEXIS AG SF0,02/ CH0106213793 /
| 2024-08-05 10:56:16 PM | Chg. -0.005 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 0.056EUR | -7.59% | - Turnover: - |
-Bid Size: - | -Ask Size: - | 3.16 mill.EUR | - | - |
GlobeNewswire
2023-09-29
Spexis provides business update and announces financial results for the first half of 2023
GlobeNewswire
2023-09-28
Spexis announces the appointment of Gonçalo Bernardes, Ph.D., as acting Head of Chemical Biology
GlobeNewswire
2023-08-15
Spexis announces USD $2.5 million capital commitment to support the upcoming Phase 3 ColiFin® studie...
GlobeNewswire
2021-06-28
Polyphor Provides Update on the Phase III FORTRESS Study of Balixafortide in Patients With Advanced ...
GlobeNewswire
2021-06-08
Polyphor Hosting Key Opinion Leader Roundtable on Covid-19: The Need for Novel Therapies for Severe ...
GlobeNewswire
2021-06-01
Polyphor's Balixafortide Demonstrates Consistent Dual Action Anti-Viral and Anti-Inflammatory Activi...
GlobeNewswire
2021-01-05
Polyphor to Take Part in Panel Discussion on Novel Oncology Targets at the LifeSci Partners 10th Ann...
GlobeNewswire
2020-12-22
Polyphor Receives Approval to Start First-in-Human Clinical Trial of Inhaled Antibiotic Murepavadin
GlobeNewswire
2020-12-14
Polyphor Announces Third Positive Data Safety Monitoring Board (DSMB) Recommendation to Continue Pha...
GlobeNewswire
2020-12-11
Polyphor Receives an Additional USD 2.3 Million Award From CARB-X to Support Ongoing Development of ...
GlobeNewswire
2020-11-24
Polyphor receives award of up to USD $3.3 million from Cystic Fibrosis Foundation to support clinica...
GlobeNewswire
2020-10-29
Polyphor completes recruitment in Phase III trial of balixafortide in metastatic breast cancer
